Evolocumab
Evolocumab is a pharmaceutical drug with 98 clinical trials. Currently 7 active trials ongoing. Historical success rate of 87.0%.
Success Metrics
Based on 60 completed trials
Phase Distribution
Phase Distribution
8
Early Stage
20
Mid Stage
58
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
83.3%
60 of 72 finished
16.7%
12 ended early
7
trials recruiting
98
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
Evolocumab in Acute Coronary Syndrome
Clinical Trials (98)
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
Evolocumab in Acute Coronary Syndrome
The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
Lipid Management in Renal Transplant Recipients Using Evolocumab.
YN001-004 in Patients With Coronary Atherosclerosis in Australia
Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation
The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk
Evolocumab in Patients With Acute MI
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction
The CHORAL Flow Study
Effect of Evolocumab on Coronary Atherosclerosis
The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 98